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Proline metabolism supports metastasis formation
and could be inhibited to selectively target
metastasizing cancer cells
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Metastases are the leading cause of mortality in patients with cancer. Metastasis formation
requires cancer cells to adapt their cellular phenotype. However, how metabolism supports
this adaptation of cancer cells is poorly deﬁned. We use 2D versus 3D cultivation to induce
a shift in the cellular phenotype of breast cancer cells. We discover that proline catabolism
via proline dehydrogenase (Prodh) supports growth of breast cancer cells in 3D culture.
Subsequently, we link proline catabolism to in vivo metastasis formation. In particular, we ﬁnd
that PRODH expression and proline catabolism is increased in metastases compared to
primary breast cancers of patients and mice. Moreover, inhibiting Prodh is sufﬁcient to impair
formation of lung metastases in the orthotopic 4T1 and EMT6.5 mouse models, without
adverse effects on healthy tissue and organ function. In conclusion, we discover that Prodh is
a potential drug target for inhibiting metastasis formation.
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M
etabolic reprogramming is recognized as a hallmark of
cancer cells that supports cancer growth1. Investigating
how metabolism supports cancer growth resulted
in several metabolism-based drugs that are now in clinical
trial2. Yet, some cancer cells within a progressing tumour acquire
additional cellular phenotypes, such as motility, invasion, survival
and colonization capacity, which are supporting cancer
progression towards metastasis formation3. Thus, identifying
how metabolism supports shifts in the cancer cell phenotype that
can contribute to metastasis formation has the potential to
identify innovative drug targets against cancer progression.
Ninety percent of all cancer deaths are caused by metastases in
distant organs4. The metastasis formation cascade consists of
several stages5,6: First, cancer cells disseminating from the
primary tumour invade the surrounding tissue and intravasate
into the circulation. Next, cancer cells inﬁltrate and colonize
a distant organ. At this stage, cancer cells can remain dormant or
in a stable micrometastasis state for weeks to years, but eventually
they will grow and form macrometastases, which results in
established secondary tumours. Several studies have focussed on
metabolic reprogramming during the early steps of metastasis
formation, when cancer cells disseminate from the primary
tumour, invade the surrounding tissue and survive in the
circulation7–9. From a clinical perspective, however, the later
steps in metastasis formation are of speciﬁc interest, because
patients often present to the clinics when cancer cells have already
inﬁltrated a distant organ10,11. Yet, our knowledge on how
metabolism supports cancer cell survival and colonization of
a distant organ is limited to a few studies7,12,13.
Here we address the questions how metabolism supports
phenotypic shifts in breast cancer cells and to which extent
inhibiting these changes in metabolism can counteract in vivo
lung metastasis formation. In particular, we enforce a phenotypic
shift in breast cancer cells by cultivating them either as monolayer
in two-dimensional (2D) culture or as spheroids in three-
dimensional (3D) culture. Next, we identify differences in the
cellular metabolism of cells cultured in 2D versus 3D conditions.
Finally, we investigate whether inhibiting the identiﬁed metabolic
differences impairs in vivo metastasis formation without adverse
effect on healthy tissue and organ function in mice. We discover
that breast cancer cells grown in spheroids (3D) compared to
attached monolayers (2D) increase proline catabolism via the
enzyme proline dehydrogenase (Prodh). Inhibiting Prodh activity
results in impaired spheroidal growth and in a dose-dependent
decrease in lung metastasis formation in two mouse models.
Pharmacological Prodh inhibition has no adverse effects in vitro
on non-transformed mammary epithelial cells and in vivo on
healthy tissue and organ function of mice. Thus we identify
Prodh as promising drug target against breast cancer-derived
metastasis formation.
Results
Proline catabolism distinguishes 2D from 3D growth. We used
transformed human MCF10A H-RasV12 mammary epithelial cells
to study phenotypic shifts induced by 2D versus 3D cultivation.
This cell line has been used to study gene expression as well as
signalling pathway activity during spheroidal growth14,15.
MCF10A H-RasV12 cells were derived from immortalized and
non-tumorigenic breast epithelial cell line MCF10A (ref. 16).
These cells were transduced with the oncogenic driver H-RasV12,
which is of relevance to the human breast cancer situation, since
50% of the human breast cancers display increased H-Ras
activity17. To achieve spheroidal growth, we cultured MCF10A
H-RasV12 cells on soft-agar coated plates in DMEM-F12 media
(Supplementary Fig. 1). To compare metabolism during
spheroidal and attached monolayer growth, we applied 13C
tracer analysis18. Since this method has so far not been used in
soft-agar cultures, we tested the suitability of four different
metabolite extraction methods19–22. We evaluated metabolite
recovery, cellular energy charge and cellular protein recovery
resulting from the four tested methods. We found that methanol–
chloroform extraction combined with a mechanical disruption of
the spheroids is well suited to extract metabolites from spheroids
cultured on soft-agar (Supplementary Fig. 2). Consequently, we
performed all our subsequent experiments using this method.
Cancer cells growing either in attached monolayers (2D) or
spheroids (3D) consume substantial amounts of the nutrients
glucose and glutamine2,23,24. Yet, it remains elusive whether
these nutrients are used to fuel metabolite production similarly
in both culture conditions. Thus, we tested the contribution
of both nutrients to organic and amino acid production in
MCF10A H-RasV12 in both conditions using 13C6-glucose and
13C5-glutamine. Interestingly, the most pronounced change
observed was a decrease in the 13C contribution from both
nutrients to the production of the amino acid proline in MCF10A
H-RasV12 (Fig. 1a,b and Supplementary Fig. 3), which indicates
that these cells switch to a different proline metabolism when
grown in spheroids.
To validate whether proline catabolism or biosynthesis are
different in MCF10A H-RasV12 cells during spheroidal growth,
we quantiﬁed proline uptake, intracellular proline levels and the
expression of PRODH and pyrroline-5-carboxylate dehydrogen-
ase (P5CDH) (proline catabolism), as well as pyrroline-5-
carboxylate synthase (P5CS) and pyrroline-5-carboxylate reduc-
tase 1 (PYCR1) (proline biosynthesis) in both growth conditions.
We found that cells consumed proline from the media only
during spheroidal growth, while the same cells secreted proline to
the media during attached monolayer growth (Fig. 1c). In
accordance, intracellular proline levels were lower in cells grown
in spheroids than the same cells grown in monolayer (Fig. 1d).
This suggested that cells grown in spheroids require more proline,
because spheroidal growth might result in proline catabolism.
Indeed, the expression of the proline catabolism enzyme PRODH
was signiﬁcantly increased by approximately 300% in MCF10A
H-RasV12 cells during spheroidal growth (Pr0.01, two-tailed
unpaired Student’s T-test) (Fig. 1e), while the expression level of
P5CDH and that of the proline biosynthesis genes P5CS and
PYCR1 remained unchanged (Fig. 1e). Together, these data
provide evidence that proline catabolism distinguishes spheroidal
(3D) from attached (2D) growth in MCF10A H-RasV12 cells.
Proline catabolism via Prodh supports 3D growth. To investi-
gate whether proline catabolism is required for spheroidal growth
of MCF10A H-RasV12 cells, we employed a genetic and catalytic
inhibition of Prodh. To this end, we generated a doxycycline
inducible CRISPR interference knockdown of PRODH in
MCF10A H-RasV12 cells, which had an efﬁciency of 96% (Supple-
mentary Fig. 4a). Strikingly, knockdown of PRODH impaired
spheroidal growth of MCF10A H-RasV12 by approximately
70% based on spheroid size (Fig. 2a).
We next tested whether inhibition of Prodh activity could elicit
a similar effect on spheroidal growth by using the compound
L-tetrahydro-2-furoic acid (L-THFA), which was reported to
inhibit Prodh activity in 2D cultures25. Since increased Prodh
activity results in decreased intracellular levels of proline
(Fig. 1d), we argued that L-THFA treatment should increase
intracellular proline levels. Consistently, we found that L-THFA
treatment increased intracellular proline levels in MCF10A
H-RasV12 spheroids (Supplementary Fig. 4b) indicating that the
compound effectively inhibits Prodh activity. Similar to the
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PRODH knockdown, L-THFA treatment reduced the spheroid
size of MCF10A H-RasV12 spheroid growth by approximately
75% (Fig. 2b). Collectively, these data show that Prodh activity
is required for optimal spheroidal growth of MCF10A H-RasV12
cells and suggested that Prodh may serve as a drug target.
Prodh activity depends on P5C recycling during 3D growth.
Subsequently, we investigated whether proline withdrawal from
the media can impair spheroidal growth. Surprisingly, we found
that proline removal from the media had no effect on the growth
of MCF10A H-RasV12 spheroids (Fig. 3a).
Interestingly, Prodh activity yields the metabolite pyrroline
5-carboxylic acid (P5C), which can be recycled to proline via
the NADPH consuming proline biosynthesis enzyme Pycr26.
Thus, we hypothesized that P5C recycling to proline via
Pycr sustains Prodh activity. Consistently, we found that the
NADPH to NADPþ ratio was decreased during spheroidal
growth (Fig. 3b).
To further conﬁrm the compensatory role of P5C recycling, we
knocked down enzymes involved in proline recycling (PYCR1,
PYCR2, PYCR3) (Supplementary Fig. 4c). Removal of proline from
the media in combination with knockdown of PYCR1 strongly
impaired spheroidal growth of MCF10A H-RasV12 (Suppleme-
ntary Fig. 4d). This implied that PYCR1 is the predominant PYCRx
isoform generating proline from P5C in MCF10A H-RasV12
spheroids. In line with the hypothesis that P5C recycling is
important for sustaining Prodh activity, we found that PYCR1
knockdown in MCF10A H-RasV12 cells impaired spheroid growth
by 73%, despite proline availability in the media (Fig. 3c,d). In
agreement with a decreased Prodh activity in PYCR1 knockdown
cells, we observed that proline levels increased compared to control
spheroids (Fig. 3e). Notably, while spheroidal growth of PYCR1
knockdown cells was decreased, the remaining spheroids addi-
tionally showed increased aggregation, which indicates an addi-
tional function of Pycr1 that is independent of sustaining Prodh
activity. This observation is in line with the ﬁnding that Pycr is
involved in nucleotide and endoplasmic reticulum homeosta-
sis26,27. Taken together, our data show that Prodh activity during
spheroidal growth is sustained by P5C recycling via Pycr1.
Prodh activity generates ATP during 3D growth. It was shown
previously that Prodh activity can contribute to mitochondrial
energy production by feeding electrons into the electron transport
chain28. To investigate whether proline catabolism via Prodh
supports ATP production in spheroids, we performed a dynamic
metabolomics experiment in MCF10A H-RasV12 spheroids upon
acute inhibition of Prodh activity using L-THFA. Interestingly,
inhibition of Prodh activity by L-THFA signiﬁcantly decreased
ATP levels in MCF10A H-RasV12 spheroids (Pr0.05, two-tailed
unpaired Student’s T-test) (Fig. 4a). Because ATP production via
Prodh requires the activity of complex III of the electron transport
chain, but not that of complex I (Fig. 4b), we hypothesized that
spheroidal growth of MCF10A H-RasV12 is more susceptible to
inhibition of complex III than of complex I. In agreement, we
found that complex III inhibitor antimycin A, but not the complex
I inhibitor rotenone, impaired spheroidal growth of MCF10A
H-RasV12 cells (Fig. 4c). Collectively, our data show that Prodh
activity supports spheroidal growth by sustaining ATP production.
Prodh activity is speciﬁcally relevant in transformed cells. Our
data suggest that Prodh may constitute a promising drug target
against metastasis formation, especially if its activity would be
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Figure 1 | Proline catabolism distinguishes 3D from 2D growth. (a) Total contribution of 13C6-glucose and
13C5-glutamine to different organic acids and
amino acids in MCF10A H-RasV12 spheroids (3D) versus attached cells (2D). Changes in total contribution 425% with a P valuer0.05 are depicted.
(b) Proline labelling from 13C6-glucose and
13C5-glutamine in MCF10A H-Ras
V12 spheroids (3D) versus attached cells (2D). (c) Proline uptake in MCF10A
H-RasV12 spheroids (3D) versus attached cells (2D). (d) Intracellular levels of proline in MCF10A H-RasV12 spheroids (3D) versus attached cells (2D).
(e) Relative expression of proline catabolism (PRODH and P5CDH) and biosynthesis (P5CS and PYCR1) genes in MCF10A H-RasV12 spheroids (3D) versus
attached cells (2D) measured by qRT–PCR. The number of biological replicates for each experiment was nZ3. All error bars represent s.d. Two-tailed
unpaired Student’s T-test was performed. *Pr0.05; **Pr0.01.
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speciﬁcally relevant for growth of transformed cells, but not of
normal cells.
Thus, we tested whether PRODH expression was increased in
transformed breast cancer cells during spheroidal growth. We
measured the expression of PRODH in cell lines isolated from
human or murine breast cancers (MCF7, HCC70, MDA-MB-231
and 4T1) during spheroidal (3D) compared to attached (2D)
growth. We found that in all tested breast cancer cell lines
PRODH expression increased during spheroidal growth (Fig. 5a).
Moreover, we conﬁrmed that 4T1 and EMT6.5 breast cancer
cell lines, which we used for subsequent in vivo studies, increased
proline uptake and were impaired by L-THFA treatment during
spheroidal growth (Fig. 5b). This suggests that Prodh is relevant
for spheroidal growth in breast cancer cell lines beyond MCF10A
H-RasV12.
Next, we tested whether Prodh activity is required for acinus
formation of non-transformed MCF10A cells, which is a normal,
non-invasive form of spheroidal growth29. Since non-transformed
MCF10A cells fail to form acini without matrix attachment, we
added 0.5% Matrigel to the DMEM-F12 media. We ruled out that
Matrigel addition signiﬁcantly changed organic and amino acid
metabolism as well as growth upon Prodh inhibition in MCF10A
H-RasV12 spheroids (P40.05, two-tailed unpaired Student’s T-test;
Supplementary Fig. 5). Interestingly, we found that PRODH
expression and ATP levels were signiﬁcantly lower in MCF10A
acini compared to MCF10A H-RasV12 spheroids (Pr0.05,
two-tailed unpaired Student’s T-test; Fig. 5c,d), suggesting that
Prodh activity is not required in non-transformed cells. In support
of this notion, Prodh inhibition by L-THFA did neither impair
acini formation nor reduce ATP levels of MCF10A cells (Fig. 5e,f).
Similarly, inhibition of complex III or complex I had no effect on
acini formation (Fig. 5g). Together, these data show that Prodh
activity in general and ATP production via Prodh in particular are
not required during normal acini formation of non-transformed
mammary epithelial cells.
Prodh activity is increased in metastases tissue. Our in vitro
data suggest that Prodh may be a drug target against metastasis
formation, which is supported by the fact that PRODH is
signiﬁcantly higher expressed in metastases compared to primary
breast cancers in patients (Pr0.01, two-tailed unpaired Student’s
T-test with Welchs correction; Fig. 6a). To test whether proline
catabolism is indeed relevant for metastasis formation, we used an
orthotopic 4T1 breast cancer mouse model. This model allowed
us to investigate primary tumours and lung metastases within
the same animal. As readout for Prodh activity, we measured
enrichment of proline from 13C6-glucose and proline levels in
4T1 primary breast cancers and the corresponding lung
metastases using in vivo 13C tracer analysis. This analysis revealed
that both parameters were reduced in lung metastases as
compared to the primary breast cancer tumours (Fig. 6b,c),
which is consistent with increased proline catabolism in metas-
tases tissue.
We next assessed potential adverse effects of the Prodh
inhibitor L-THFA in mice. Since L-THFA was, to our knowledge,
never applied in vivo, we measured alterations in metabolite levels
in MCF10A H-RasV12 spheroids upon treatment with L-THFA to
deﬁne which metabolic changes need to be monitored in vivo to
exclude adverse effects on healthy tissue. We found that mainly
proline, alanine, glutamate, fumarate and malate levels were
signiﬁcantly changed upon treatment with L-THFA (Pr0.05,
two-tailed unpaired Student’s T-test; Fig. 6d). Since Prodh is
physiologically expressed at high levels in the brain, heart and
liver (human protein atlas), we measured the levels of the ﬁve
metabolites in the brain, heart and liver of BALB/c mice treated
with increasing doses of L-THFA (30, 45, 60mg kg 1). The
compound was administered daily via intraperitoneal injections
and metabolite levels were measured at day 16 of treatment. We
found that only the lowest tested dose of L-THFA treatment did
not result in a substantial increase in proline levels in these organs
(Fig. 6e). Moreover, at this dose only minor and non-signiﬁcant
changes in alanine, glutamate, fumarate and malate levels were
observed (P40.05, two-tailed Student’s T-test with F-testing to
conﬁrm equal variance).
To investigate the adverse effects beyond the level of central
metabolism, we performed a full plasma/blood analysis and
histopathology on BALB/c mice injected for 16 days with
30mg kg 1 L-THFA. This analysis showed that L-THFA
treatment at this dose did not result in signiﬁcant changes in
haematology, clinical chemistry and organ histopathology
compared to vehicle treatment of BALB/c mice (P40.05,
two-tailed Student’s T-test with F-testing to conﬁrm equal
variance; Supplementary Fig. 6). Based on this analysis, we
decided to treat mice for all consecutive experiments with an
L-THFA dose of r30mg kg 1, which allowed safe administra-
tion for at least 16 days without obvious adverse effects.
Prodh inhibition impairs lung metastases formation. Finally,
we tested whether inhibition of Prodh activity is sufﬁcient to
impair in vivo metastasis formation in the 4T1 orthotopic breast
cancer mouse model30. We induced primary tumour growth by
injection of 4T1 breast cancer cells to the mammary fat pad of
6-week-old BALB/c mice. After 4 days when the primary tumour
nodule was established and palpable, we started daily
intraperitoneal injections of L-THFA at r30mg kg 1. Sixteen
days after treatment, we analysed proline levels (to conﬁrm Prodh
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Figure 2 | Proline catabolism via Prodh supports 3D growth. (a) Representative pictures and size quantiﬁcation of MCF10A H-RasV12 spheroids
transduced with an inducible lentiviral CRISPR with or without guide for PRODH. CRISPR expression was induced with 0.1 mgml 1 doxycycline. Analysis
was performed 5 days after PRODH knockdown (KD) induction. (b) Representative pictures and size quantiﬁcation of MCF10A H-RasV12 spheroids with or
without L-THFA treatment. Treatment was started at day 0. Analysis was performed at day 5 of treatment. Scale bar: 150mm. The number of biological
replicates for each experiment was nZ3. All error bars represent s.d. Two-tailed unpaired Student’s T-test was performed. **Pr0.01; ***Pr0.001.
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inhibition in the metastases) and the number of metastases in the
lungs as well as the primary breast tumour weight.
We found that proline levels were lower in the metastasis tissue
compared to the primary breast cancer tissue only in animals
treated with vehicle (Fig. 6c). Upon L-THFA treatment, this
difference was not present anymore (Fig. 6c), which showed that
L-THFA treatment resulted in the expected inhibition of Prodh
activity within the metastasis tissue.
Strikingly, the weight of the primary breast cancer tumours
remained unchanged upon L-THFA treatment (Fig. 7a), whereas the
number of surface lung metastases decreased in a dose-dependent
manner, with the strongest reduction in metastases (B60%) at 30mg
kg 1 (Fig. 7b,c). Next, we performed haematoxylin and eosin (H&E)
staining of the lungs from animals treated with this dose, which
conﬁrmed the signiﬁcantly reduced total number of metastases per
lung section by approximately 50% (Pr0.05, two-tailed
Student’s T-test with Welch’s correction) (Fig. 7d,e). Finally, we
validated the effect of Prodh inhibition on metastasis formation in
the orthotopic EMT6.5 breast cancer mouse model30,31 (Fig. 7f–h).
In summary, our data demonstrate that Prodh inhibition is
sufﬁcient to impair formation of breast cancer-derived lung
metastases.
Discussion
Here we show that proline catabolism via Prodh distinguishes
breast cancer cells growing in spheroids (3D) from those growing
in attached (2D) conditions. Inhibiting Prodh activity speciﬁcally
impairs the capacity of breast cancer cells to form spheroids in vitro
and lung metastases in vivo. Treatment with the Prodh inhibitor
L-THFA had no adverse effects on non-transformed cells in vitro
and in vivo. Thus, our data suggest Prodh as a promising drug
target for preventing lung metastasis formation in breast cancer.
Unlike many other non-essential amino acids, the catabolism
and biosynthesis of proline is catalysed by two different enzymes,
namely Prodh and Pycr, that are coupled to two different
co-factors. Thus, various roles of proline metabolism in
transformed and non-transformed cells are possible. Indeed,
inhibition of proline biosynthesis has been linked to unresolved
endoplasmic reticulum stress in yeast and in cancer cells27,32.
Moreover, it has been shown that proline biosynthesis can
contribute to sustaining intracellular nucleotide levels26. In
certain cancer cells, proline biosynthesis inhibition was found
to impair tumorigenic potential and to decrease attached
monolayer growth26,27. Yet, inhibition of proline catabolism
in attached monolayer cultures resulted across different
in vitro studies in both anti- and pro-growth/survival
effects28,33–39. Moreover, the in vivo role of Prodh activity in
cancers has so far not been studied. This is challenging for
advancing Prodh as a drug target, since it remains unclear under
which in vivo conditions Prodh can be targeted to counteract
cancer. We discovered that Prodh activity speciﬁcally impairs
in vitro spheroidal growth and in vivo metastasis formation of
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breast cancer cells. Moreover, we show that treatment with
the Prodh inhibitor L-THFA does not result in any adverse
effects in normal cells and organ function (evaluated by organ
metabolomics, haematology, clinical chemistry and organ
histopathology) in mice. Thus, our study highlights Prodh as
promising and likely safe therapeutic target for preventing breast
cancer-derived metastasis formation.
In contrast to our recent ﬁnding that pyruvate carboxylase-
dependent anaplerosis distinguishes the metabolism of primary
breast cancers from that of the resulting lung metastases due to
the nutrient microenvironment13,40,41, the data presented here
indicate that the dependence of lung metastases on Prodh activity
is driven by shifts in the cellular phenotype. In accordance,
proline catabolism seems to be speciﬁcally important during early
stages of metastatic growth but less relevant in established
secondary tumours. Consistent with this notion, we found that
PRODH expression inversely correlated with spheroid size
(Supplementary Fig. 7a) and that L-THFA treatment started
after spheroid formation did not impair spheroid growth any
longer (Supplementary Fig. 7b). Also, these data are consistent
with the recent ﬁnding that MYC, which negatively regulates
PRODH expression34, shows lower expression in micrometastases
(deﬁned by signatures of quiescent and dormancy genes)
than macrometastases42. Consistently, we found that MYC
expression is inversely correlated with PRODH expression in
primary breast cancer tissue compared to metastases tissue of
patients (Fig. 6a and Supplementary Fig. 7c).
The ability of cancer cells to perform phenotypic shifts is only
one aspect of metastasis formation, and multiple other factors,
including the extracellular matrix composition and stiffness, are
important additional factors for metastasis formation43,44. Hence,
it is tempting to speculate that the need of breast cancer cells for
proline catabolism may depend on speciﬁc site/organ of
metastasis. However, the ﬁnding that MYC, which negatively
regulates PRODH expression, clusters with metastasis size rather
than with the metastatic site42, suggests that Prodh inhibition
may be independent of the organ in which metastases form.
Our data suggest that targeting Prodh activity could have the
potential to be effective against dormant breast cancer cells
and micrometastases. Notably, targeting such cancer cells is of
speciﬁc interest for breast cancer treatment, because inﬁltration of
distant organs leading to micrometastases formation is a very
early event that often occurs before the primary tumour is
resected10,11 and which results years later in established
secondary tumours and 90% of breast cancer deaths2.
In summary, we identify Prodh as promising drug target
against breast cancer-derived metastasis formation.
Methods
Cell culture. We generated MCF10A cells expressing H-RasV12 (MCF10A
H-RasV12) as well as control cells expressing an empty pLA vector (MCF10A)
(Supplementary Fig. 1a). MCF10A and MCF10A H-RasV12 cells were grown in
DMEM-F12 supplemented with 5% horse serum, 1% penicillin (50 units ml 1),
1% streptomycin (50 mgml 1), 0.5 mgml 1 hydrocortisone, 100 ngml 1 cholera
toxin, 10mgml 1 insulin and 20 ngml 1 recombinant human EGF. MCF7,
HCC70 and MDA-MB-231 cells were cultured in DMEM supplemented with
10% fetal bovine serum, 1% penicillin (50 unitsml 1), 1% streptomycin
(50 mgml 1) and 0.15mM proline. 4T1 cells were cultured in Roswell Park
Memorial Institute medium with pyruvate supplement, 10% fetal bovine serum,
1% penicillin (50 unitsml 1) and 1% streptomycin (50 mgml 1). All cell lines
were conﬁrmed to be mycoplasma-free by the Mycoalert Detection Kit (Lonza).
MCF10A, MCF7, HCC70, MDA-MB-231 and 4T1 cell lines were purchased
from ATCC. All human cell lines were validated by DNA ﬁngerprinting. The
EMT6.5 cell line is a single-cell clone from the EMT6 cell line available from
ATCC31 and kindly provided by Professor Robin Anderson (Peter MacCallum
Cancer Centre). None of the cell lines used for this study are listed in the database
of commonly misidentiﬁed cell lines maintained by ICLAC. Both the 4T1 and
EMT6 cell line-based orthotopic mouse models are widely used and accepted
models for metastasis research30. Primary breast cancer of these models
spontaneously metastasize within a short time frame and with a 100% penetrance.
Two different 3D growth conditions were tested (Supplementary Fig. 1): For
soft-agar culture, a base layer of agar was prepared in six-well plates. Soft-agar was
dissolved at 1% in sterile distilled water in a microwave oven and was mixed with
prewarmed (37 C) medium at a ratio of 1:1. The base layer of agar mixture was
transferred into a six-well plate at 3ml per well. Soft-agar was left to solidify at room
temperature. Reduced growth factor Matrigel (0.5%) without phenol red was added
into the cold DMEM-F12 media before the seeding by using tips precooled to
 20 C. MCF10A cells were plated on top of the base agar at 15,000 cells per well.
For ultra-low attachment, cells were suspended sparsely and plated at 15,000 cells per
well in six-well ultra-low Corning attachment plates. Unless otherwise noted,
MCF10A H-RasV12 were cultured on soft-agar without Matrigel addition. For 13C
carbon incorporation from glucose (Cambridge Isotope Laboratories, 99%) and
glutamine (Sigma, 98%), cells were incubated for 5 days with labelled substrates. All
analyses were performed after 5 days of incubation at 37 C in a 5% CO2 incubator.
L-THFA was purchased from Sigma-Aldrich and used at the concentration of
5mM (MCF10A, MCF10A H-RasV12 and 4T1 cells) and 10mM (EMT6.5 cells).
The compound was added at day 0 and pictures were taken at day 5. For ATP
analysis, L-THFA was used at day 5 for 0, 20 and 30min at the concentration of
10mM. Rotenone and Antimycin A were purchased from Sigma-Aldrich and used
at the concentration of 5 and 2 mM, respectively. The compounds were added at
day 0 and pictures were taken at day 5. All growth experiments were performed in
nZ3 biological replicates.
shRNA knockdowns. The lentiviral pLKO shPYCR1 (NM_153824.1-398s1c1),
shPYCR2 (NM_013328.2-996s1c1), shPYCR3 (NM_023078.x-1629s1c1) and scram-
bled control were purchased from the Broad Institute (Supplementary Table 1).
CRISPR interference knockdowns. The lentiviral CRISPR interference plasmid
pHR-SFFV-KRAB-dCas9-P2A-mCherry was obtained from AddGene (Plasmid
#60954). Inducibility was achieved by subcloning the KRAB-dCas9-P2A-mcherry
behind the TetO promoter of the lentiviral pTripZ vector (Open Biosystems
RHS4750) through Gibson cloning. The U6 promoter and tracer sequence were
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Figure 4 | Prodh activity generates ATP during 3D growth. (a) Time-
resolved ATP levels of MCF10A H-RasV12 spheroids upon treatment with the
Prodh inhibitor L-THFA. (b) Schematic representation of Rotenone and
Antimycin A mode of action as well as ATP generation from proline
catabolism. (c) Representative pictures of MCF10A H-RasV12 spheroids upon
treatment with either rotenone or antimycin A. Treatment was started at day
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number of biological replicates for each experiment was nZ3. All error bars
represent s.d. Two-tailed unpaired Student’s T-test was performed. *Pr0.05.
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cloned from pX330-U6-Chimeric-BB-CBh-hSpCas9, obtained from AddGene
(Plasmid #42230) through Gibson cloning. Guide speciﬁc for PRODH was selected
by using the online guide design website available from http://crispr.mit.edu. From
these, the top guide (GGCCCTGTAGTGCCGAAGCA) was selected and cloned
30 to the U6 promoter through Gibson cloning45,46. Lentiviral particles were
produced in HEK293 cells. MCF10A and MCF10A H-RasV12 cells were selected
with puromycin 1 mgml 1. The expression of the CRISPR was induced with
doxycycline 0.1 mgml 1. As a control, an inducible CRISPR line lacking the guide
for PRODH was generated.
Flow cytometry. In brief, MCF10A cells and MCF10A-derived colonies were lysed
in trypsin 0.05% and 1 106 single cells were resuspended and incubated with
antibodies at concentrations of 0.2 mg per 100 ml for CD24 conjugated with
phycoerythrin (PE) (12-0247-42) and 0.1 mg per 100ml for CD44 conjugated with
PE-cyanine7 (Cy7) (560533), both purchased from BD Biosciences. Samples were
stained in ice in the dark for 15min, and then the cells were washed twice with cold
PBS, resuspended in 400ml PBS and analysed using a ﬂow cytometer (BD FACS
Verse). As negative controls, cells were treated with either isotype-matched control
antibodies or with no primary antibody.
RNA isolation and quantitative real-time PCR. Total RNA was isolated with
the PureLink RNA Mini Kit (Life Technologies). RNA (400 ng) was reverse
transcribed into cDNA using a High-Capacity cDNA Reverse Transcription Kit
(Life Technologies). The relative levels of gene transcripts compared to the control
gene RPL-19 were determined by quantitative real-time PCR using SYBER Green
PCR Master Mix (Life Technologies) and speciﬁc primers on a 7,500 Fast Real Time
PCR System (Applied Biosystems, Life Technologies) (Supplementary Table 2).
Ampliﬁcation was performed at 95 C for 10min, followed by 40 cycles of 15 s at
95 C and 1min at 60 C. The fold change in gene expression was calculated as:
Fold change ¼2DDCt
Quenching and metabolite extraction methods. The quenching procedure
applied was adapted from Sellick et al.47. Fifty-ml falcon tubes with methanol
60% and 10mM ammonium acetate were precooled in a dry ice-ethanol bath
( 40 C) for 20min. Colonies were transferred with a 1,000 ml pipette from the
soft-agar plates to 15ml falcon tubes and pelleted by centrifugation (1,400 r.p.m.,
1min, room temperature) to remove excess of medium. In this step, four wells of
one six-well plate were pooled into one falcon tube (one replicate). Medium was
aspirated by using a vacuum line and the remaining cell pellet was immediately
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added to the 50ml falcon tube containing 5ml of the quenching solution at
 40 C. Cells were pelleted by centrifugation (2,000 r.p.m., 30 s, room
temperature) and the supernatant was removed by quickly inverting the tube. The
cell pellet was washed a second time with quenching solution ( 40 C). After the
second wash, the cell pellet was stored at  80 C.
Four different extractions methods were tested. All the extraction procedures
were performed in a dry ice-ethanol bath ( 40 C). The protocols were adapted
from the established published methods. The details of each procedure are
described separately below. The methanol/chloroform extraction procedure was
adapted from de Koning et al.19. The samples were resuspended in 800 ml of
precooled 60% methanol, before 500ml of precooled chloroform were added.
Samples were vortexed for 10min at 4 C and then centrifuged (max. speed,
10min, 4 C). The upper methanol/water phase, the intermediate protein layer and
the lower chloroform phase were collected separately.
The hot ethanol extraction procedure was adapted from Bent et al.20. Ethanol
75% was preheated in a water bath at 80 C for 20min. Hot ethanol (1ml) was
poured over the cell pellet. The samples were immediately vortexed and then
placed in the water bath for 3min. After the 80 C incubation, the samples were
placed back in the cold bath ( 40 C) and then centrifuged (max. speed, 5min,
4 C). The supernatants and the proteins were collected separately.
The trichloroacetic acid extraction procedure was adapted from
Tunnicliffe et al.22. Samples were resuspended in precooled 5% trichloroacetic
acid and then centrifuged (max. speed, 5min, 4 C). The supernatants and the
protein were collected separately.
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The Acetonitrile–Methanol Extraction procedure was adapted from
Rabinowitz et al.21. Each sample was resuspended in 1ml of precooled
acetonitrile/methanol/water (40:40:20) and centrifuged (max. speed, 5min, 4 C).
The supernatants and the protein were collected separately.
By using a tissue lyser, a mechanical disruption step was performed after
resuspension of the cell pellet with the chemicals of the respective extraction
method at  40 C for 5min.
The extracts were dried using a vacuum concentrator. Fatty acids were dried at
20 C for 1 h, while polar metabolites were dried at 4 C over night. The samples
were stored at  80 C.
Gas chromatography–mass spectrometric analysis. Metabolites were deriva-
tized and measured as described before48. In brief, polar metabolites were
derivatized with 20mgml 1 methoxyamine in pyridine for 90min at 37 C and
subsequently with N-(tert-butyldimethylsilyl)-N-methyl-triﬂuoroacetamide, with
1% tert-butyldimethylchlorosilane for 60min at 60 C. Fatty acids were esteriﬁed
with sulfuric acid/methanol for 72 h at 60 C and then extracted with hexane.
Metabolites were measured with a 7890A GC system (Agilent Technologies)
combined with a 5975C Inert MS system (Agilent Technologies). One microlitre of
samples was injected in splitless mode with an inlet temperature of 270 C onto a
DB35MS column. The carrier gas was helium with a ﬂow rate of 1mlmin 1. For
the measurement of polar metabolites, the GC oven was held at 100 C for 3min
and then ramped to 300 C with a gradient of 2.5 Cmin 1. For the measurement
of fatty acids, the oven was held at 80 C for 1min and ramped with 5 Cmin 1 to
300 C. The MS system was operated under electron impact ionization at 70 eV and
a mass range of 100–650 a.m.u. was scanned.
Mass distribution vectors were extracted from the raw ion chromatograms
using a custom Matlab M-ﬁle, which applies consistent integration bounds and
baseline correction to each ion. Moreover, we corrected for naturally occurring
isotopes using the method of Fernandez et al.49. Total contribution of carbon was
calculated using the following equation18:
Total contribution of carbon ¼
Pn
i¼0 imi
nPni¼0 mi
Here n is the number of C atoms in the metabolite, i the different mass isotopomers
and m the abundance of a certain mass. For metabolite levels, arbitrary units of the
metabolites of interest were normalized to an internal standard and protein
content (in vitro experiments) or tissue weight (in vivo experiments). In vivo, the
13C enrichment of glucose in the blood of the mice was evaluated and conﬁrmed to
be similar between the infused animals.
Liquid chromatography–mass spectrometric analysis. Polar metabolites were
resuspended in 60% acetonitrile. Metabolites were measured using a Dionex
UtiMate 3,000 LC System (Thermo Scientiﬁc) combined with a Q Exactive
Orbitrap mass spectrometer (Thermo Scientiﬁc) and run in negative mode, using
mass spectrometry based on accurate mass. Samples were injected onto a SeQuant
ZIC/pHILIC Polymeric column (Merck Millipore)50. The solvent, composed of
acetonitrile and ammonium acetate (pH¼ 9.3, 10mM), was used at a ﬂow rate of
0.100mlmin 1. Data analysis was performed with the Xcalibur software.
Metabolite levels were normalized to a fully 13C-labelled yeast extract and protein
content. Alternatively, targeted measurements of polar metabolites were performed
with a 1,290 Inﬁnity II HPLC (Agilent) coupled to a 6,470 triple quadrupole mass
spectrometer (Agilent). Samples were injected onto a iHILIC-Fusion(P) column
with the above-mentioned solvents. Data analysis was performed with the Agilent
Mass Hunter software.
Analysis of gene expression microarray data. Microarray data of primary breast
cancers (GSE20711)51 and breast cancer metastases (GSE14017)52 generated on
Affymetrix HG-U133Plus2.0 chips were retrieved from the Gene Expression
Omnibus and normalized simultaneously by Robust Multichip Average53 using
custom brain array chip description ﬁles (v18, ENTREZG) yielding one optimized
probe-set per gene54. Statistical signiﬁcance of differences in the gene expression
levels were analysed with a two-tailed unpaired Student’s T-test with Welch’s
correction using the GraphPad Prism 5 software (GraphPad Software Inc.).
In vivo 13C tracer infusions. Six-week-old female BALB/c mice were orthotopi-
cally inoculated with one million 4T1 cells. Primary tumour growth and body
weight was monitored every second day. One week after tumour initiation, surgical
catherization of the jugular vein was carried out as follows: BALB/c mice were
anesthetized with 3% isoﬂurane with 2% oxygen and a catheter was placed into the
right jugular vein. A small incision between shoulder blades was made and the
catheter was exteriorized at the back of the mouse and connected to an antenna
part, which enables conscious handling of the mouse during infusion. The tubing
was ﬂushed with heparinized saline directly after the surgery and 3 days later.
Animals were individually housed after surgery, and painkillers were administered
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Figure 7 | Prodh inhibition impairs lung metastases formation. (a) Primary tumour weight, (b) the number of surface lung metastases and
(c) representative pictures of ink-stained lungs with white tissue indicating metastases of BALB/c mice orthotopically injected with murine 4T1 breast
cancer cells treated with vehicle or L-THFA at different concentrations for 16 days: 0mg kg 1 (n¼ 36, 4 independent cohorts), 7.5mg kg 1 (n¼9),
15mg kg 1 (n¼ 8), and 30mg kg 1 (n¼ 21, 3 independent cohorts). Treatment was started after primary breast tumours were formed. Scale bar: 0.5 cm.
Two-tailed unpaired Student’s T-test with Welch’s correction was performed. **Pr0.01; ***Pr0.001. (d) Number of lung metastases per lung section and
(e) representative pictures of H&E-stained lung sections of BALB/c mice orthotopically injected with murine 4T1 breast cancer cells treated with vehicle or
L-THFA at 30mg kg 1 (n¼ 5 per condition). Scale bar: 2.7mm. Two-tailed Student’s T-test with F-testing to conﬁrm equal variance was performed.
*Pr0.05. (f) Primary tumour weight, (g) the number of surface lung metastases and (h) representative pictures of ink-stained lungs (black) with
metastases (white) of BALB/c mice orthotopically injected with murine EMT6.5 breast cancer cells treated with vehicle (n¼ 9) or L-THFA at 15mg kg 1
(n¼8) for 18 days. Scale bar: 0.5 cm. Two-tailed Student’s T-test with F-testing to conﬁrm equal variance was performed. *Pr0.05. All error bars
represent s.e.m.
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(Carprofen, 5mg kg 1 body weight subcutaneously) during surgery and 1 day
there after13,55,56.
Two weeks after surgery, 13C6-labelled glucose (99% enriched; Sigma-Aldrich)
infusions were performed (n¼ 4). Mice were subjected to a continuous infusion of
0.03mg 13C-labelled glucose per gram body weight per min for the course of 6 h
with a glucose solution of 500mg perml 13C-labelled glucose. Subsequently, mice
were killed using nembutal, blood was collected and the breast tumours and lung
metastases were placed in cold saline, dissected ino3min and immediately frozen
using a liquid nitrogen cooled Biosqueezer (Biospec Products). The tissue was
weighed (10–15mg) and pulverized (Cryomill, Retsch) under liquid nitrogen
conditions. The pulverized tissue was extracted for GC-MS and LC-MS analysis as
described above. Additionally, blood enrichment of 13C glucose was analysed to
ensure that no signiﬁcant differences in blood enrichment per animal are observed.
The animal study complies with ethical regulation and was approved by the KU
Leuven ethics committee.
In vivo drug treatment. Six-week-old female BALB/c mice were orthotopically
inoculated with one million of either 4T1 or EMT6.5 cells. For inhibition of Prodh
activity, L-THFA treatment was started after 4 days when the primary tumour
nodule was established and palpable. Different doses of L-THFA (60mg kg 1
(n¼ 6), 45mg kg 1 (n¼ 6), 30mg kg 1 (n¼ 21 with 3 independent cohorts),
15mg kg 1 (n¼ 8), 7.5mg kg 1 (n¼ 9)) were injected daily intraperitoneally to
healthy or cancer-bearing mice. L-THFA was dissolved in PBS and pH neutralized
with NaOH. PBS was injected as a vehicle to control animals (n¼ 36 with 4
independent cohorts). L-THFA-treated and control mice were randomly chosen.
Mice were killed after 16 days (4T1 model) or 18 days (EMT6.5 model) of treat-
ment. In case of cancer-bearing mice, lung metastases were visualized by intra-
tracheal injection of ink solution (15% of ﬁnal volume of black ink, water, 2–3
drops ammonia). Black ink-injected lungs were washed in distaining solution
(100ml 70% EtOH, 100ml 37% formaldehyde, 5ml glacial acetic acid) and then
placed in fresh distaining solution overnight. Two different researchers in a blind
manner counted white tumour nodules against a black lung background. The
animal study complies with ethical regulation and was approved by the KU Leuven
ethics committee.
In vivo histopathology analysis. A short-term toxicology study was carried out in
order to rule out potential adverse effect/toxicity of the drug under the same
treatment conditions used for the original efﬁcacy study. Brieﬂy, six-week-old
BALB/c females were randomly divided into two groups (n¼ 5 per group) and
treated with 30mg kg 1 of L-THFA (group I) or vehicle only (group II) once a day
for 16 days via peritoneal injection. During the treatment period, the following
clinical, physiological and behavioural parameters were constantly monitored and
recorded: body weight, food and water consumption, body condition score, home
cage activity, and locomotion. Twenty-four hours after the last injection, animals
were killed by CO2 asphyxiation. Terminal blood collection was also performed via
cardiac puncture. Next, the mice underwent complete necropsy with gross
examination and organ weights. The following organs/tissues were ﬁnally sampled
and immersion ﬁxed for 48–72 h in 10% neutral buffered formalin: truncal skin,
entire head, spine, salivary glands, esophagus, larynx, trachea, lungs, heart,
gastrointestinal tract, liver and gall bladder, pancreas, kidneys, ovaries, uterus,
urinary bladder, lymph nodes (cervical, mesenteric), spleen, thymus, left hindlimb,
and sternum.
Formalin-ﬁxed tissues samples were routinely processed and embedded in
parafﬁn blocks for histopathological examination (Thermo Scientiﬁc Excelsior AS
Tissue Processor and HistoStar Embedding Workstation). 5 mm thick sections
obtained from these blocks (Thermo Scientiﬁc Microm HM355S microtome) were
then stained with H&E (Leica ST5010 Autostainer XL) and evaluated under a Leica
DM 2,500 light microscope by a board-certiﬁed veterinary pathologist. Trimming
and orientation of the various organs/tissues collected were performed following
the RITA guidelines (revised guides for organ sampling and trimming in rats and
mice). Microscopic lesions observed during histopathological examination were
classiﬁed according to the INHAND (International Harmonization of
Nomenclature and Diagnostic Criteria) system. Histopathological examination was
performed in a blind manner and details concerning experimental design and
tested compounds were revealed only at the end of the study. Whole-blood samples
were collected in BD Microtainer K2E tubes (ref. #365955). Haematology was
performed using the scil Vet abc Plus analyser. Clinical chemistry was conducted
on plasma separated from the whole blood.
For the quantiﬁcation of pulmonary metastasis, dissected lung samples were
gently infused via the trachea with 10% neutral buffered formalin and then
processed for histopathological examination as previously described. 5 mm thick
sections obtained from the resulting parafﬁn blocks were stained with H&E.
Reconstruction and absolute counts of metastatic lesions were ﬁnally performed on
four step sections with an interval of 30 mm and therefore spanning an overall
parenchymal thickness of 110 mm. The animal study complies with ethical
regulation and was approved by the KU Leuven ethics committee.
Statistical analysis. Two-tailed unpaired Student’s T-tests were performed on
nZ3 biological replicates. For the in vivo data, statistical signiﬁcance was calculated
by standard two-tailed Student’s T-tests with F-testing to conﬁrm equal variance.
In case of unequal variance, Welch’s correction was performed. Detection of
mathematical outliers was performed using Grubb’s test in GraphPad. Sample size
for all experiments was chosen empirically. Independent experiments were pooled
and analysed together whenever possible as detailed in ﬁgure legends. All graphs
show mean±s.d. or s.e.m. as indicated in the ﬁgure legends.
Data availability. Microarray data of primary breast cancers (GSE20711)51 and
breast cancer metastases (GSE14017)52 generated on Affymetrix HG-U133Plus2.0
chips are available through Gene Expression Omnibus. The authors declare that all
the other data supporting the ﬁndings of this study are available within the article
and its Supplementary Information ﬁles and from the corresponding author upon
reasonable request.
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